TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

about

Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.

P2860

Q52653323-F34832A2-7184-4919-902A-6C67E24FBF6C

P2860

TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

Item

http://www.wikidata.org/entity/Q45064262

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

@en

TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

@nl

type

Item

label

TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

@en

TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

@nl

prefLabel

TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

@en

TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

@nl

P1476

TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

@en

P2093

Timothy Nj Bullock

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunotherapy: moving beyond current vaccines

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

Influence of immunoglobulin isotype on therapeutic antibody function

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Immune checkpoint blockade: a common denominator approach to cancer therapy

Comparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responses

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.

CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8+ T-cell responses.

GITR agonist enhances vaccination responses in lung cancer.

P304

70-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.COI.2017.07.005

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28750279

http://www.w3.org/2001/XMLSchema#string

P932

5626616

http://www.w3.org/2001/XMLSchema#string

TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

about

P2860

P2860

TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932